Journal 8, August 2022pages: 491-496
1Departments of Otolaryngology-Head and Neck Surgery
2Radiotherapy, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel
3Department of Hematology-Oncology, Schneider Children's Medical Center, Petah Tikva, Israel
4Pediatric Hematology Laboratory, Felsenstein Medical Research Center, Petah Tikva, Israel
5Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Background: Recent studies show a high risk of developing malignancy in patients with Fanconi anemia. The most common solid tumor in this condition is head and neck squamous cell carcinoma (HNSCC) and there is often uncertainty and about disease behavior as well as chemotherapy and radiation response.
Objectives: To describe and characterize HNSCC among Fanconi anemia patients on the Israeli Fanconi Registry
Methods: Our study population included patients in Israel's inherited bone marrow failure registry who were diagnosed with Fanconi anemia between1980 and 2016. Demographic, clinical, and laboratory data were collected from patient charts.
Results: From the collected data, HNSCC was confirmed in 6/111 (5.4%) Fanconi anemia patients; 1 (17%) had classic HNSCC risk factors of tobacco abuse and 4 (56%) had undergone primary surgery. The 3 (50%) receiving concurrent chemoradiotherapy had mild side effects, while half developed metachronous primary malignancy, and all developed > 2 primary malignancies. The overall median survival of the patients in our study was 14 (0.5–57) months.
Conclusions: Fanconi anemia patients have a very high risk of developing HNSCC. Proactive screening for malignancies is needed for the head and neck regions. We also found that chemoradiotherapy can be used safely in high-stage cancers.